Nivolumab plus Ipilimumab versus Platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: safety analysis from CheckMate 227
CheckMate 227 is a large phase 3 study of first-line Nivolumab plus Ipilimumab, Nivolumab, or Nivolumab plus chemotherapy vs chemotherapy in advanced non-small cell lung cancer ( NSCLC ).
The study met its co-primary endpoint demonstrating significantly prolonged progression-free survival with Nivolumab plus Ipilimumab versus chemotherapy in patients with tumor mutational burden greater than or equal to 10 mutations/Mb.
The safety profile of first-line Nivolumab plus low-dose Ipilimumab was consistent with previous reports.
Patients ( n=1739 ) with chemotherapy-naive, stage IV / recurrent NSCLC without known sensitizing EGFR / ALK mutations were randomized 1:1:1 to Nivolumab ( 3 mg/kg Q2W) plus Ipilimumab ( 1 mg/kg Q6W ), Nivolumab monotherapy ( 240 mg Q2W ), or chemotherapy for patients with greater than or equal to 1% tumor PD-L1 expression and to Nivolumab plus Ipilimumab, Nivolumab ( 360 mg Q3W ) plus chemotherapy, or chemotherapy for patients with less than 1% tumor PD-L1 expression.
Treatment continued until disease progression or unacceptable toxicity for up to 2 years.
Safety and patient-reported outcomes were exploratory endpoints. Safety analyses included time to onset and resolution of select treatment-related adverse events ( select TRAEs; those with a potential immunologic cause ) and corticosteroid use. Patient-reported outcomes were assessed using the Lung Cancer Symptom Scale and EQ-5D instruments.
Minimum follow-up was 11.2 months. Median duration of therapy was 4.2 months with Nivolumab plus Ipilimumab and 2.6 months with chemotherapy.
Rates of any grade and grade 3–4 treatment-related adverse events were 75% and 31% with Nivolumab plus Ipilimumab, and 81% and 36% with chemotherapy, respectively.
Treatment-related adverse events led to discontinuation in 17% of patients receiving Nivolumab plus Ipilimumab and in 9% of patients receiving chemotherapy.
Most frequent grade 3–4 select treatment-related adverse events in patients receiving Nivolumab plus Ipilimumab were hepatic ( 8% ), endocrine ( 4% ), skin ( 4% ), pulmonary ( 3% ), and gastrointestinal ( 2% ).
Median time to onset of select treatment-related adverse events ranged from 2–15 weeks, and the majority resolved with corticosteroid use ( median time to resolution was less than or equal to 10 weeks ).
In CheckMate 227, Nivolumab plus low-dose Ipilimumab was well tolerated in non-small cell lung cancer.
Toxicities were manageable with previously established treatment algorithms, including corticosteroids. ( Xagena )
Source: American Society of Clinical Oncology - ASCO Meeting, 2018
Primary analysis of CITYSCAPE study of the anti-TIGIT antibody Tiragolumab plus Atezolizumab versus Atezolizumab as first-line treatment in patients with PD-L1-selected NSCLC
The immunomodulatory receptor TIGIT is a novel inhibitory immune checkpoint present on activated T cells and NK cells in multiple...
Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer: results from GEOMETRY mono-1 study
In the ongoing, multicohort, phase 2 GEOMETRY mono-1 study, Capmatinib ( Tabrecta ) has shown efficacy in METex14–mutated non–small cell...
Hyperprogressive disease in advanced non–small cell lung cancer patients treated with immune checkpoint inhibitors
Hyperprogressive disease ( HPD ) is a paradoxical boost in tumour growth described in a subset of cancer patients treated...
Pembrolizumab in combination with chemotherapy has improved overall survival versus chemotherapy alone as first-line treatment for patients with advanced NSCLC whose tumors do not express PD-L1
The first-line treatment with Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with chemotherapy has demonstrated improvements in overall...
FDA has warned about rare but severe lung inflammation with Ibrance, Kisqali, and Verzenio for breast cancer
The FDA ( U.S. Food and Drug Administration ) has warned that Ibrance ( Palbociclib ), Kisqali ( Ribociclib ),...
The European Commission has granted marketing authorization in the European Union ( EU ) for the precision oncology treatment Vitrakvi...
Keytruda as first-line treatment for metastatic or unresectable recurrent head and neck squamous cell carcinoma: two new regimens approved by European Commission
The European Commission ( EC ) has approved Keytruda , an anti-PD-1 therapy, as monotherapy or in combination with Platinum...
Ibrance: FDA has expanded approved use of metastatic breast cancer treatment to include male patients
The FDA ( U.S. Food and Drug Administration ) has extended the indication of Ibrance ( Palbociclib ) capsules in...
FDA has approved Piqray, the first PI3K inhibitor for HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer
The FDA ( U.S. Food and Drug Administration ) has approved Piqray ( Alpelisib ) tablets, to be used in...
Lorviqua for treatment of adult patients with ALK-positive advanced non-small cell lung cancer, previously treated with one or more ALK tyrosine kinase inhibitors: approved in European Union
The European Commission ( EC ) has granted conditional marketing authorization for Lorviqua ( Lorlatinib, available in the U.S., Canada...